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A 65-year-old Japanese male with therapy-related myelodysplastic syndrome was admitted for unrelated cord blood
transplantation. A cord blood unit from a male donor was obtained from the Japan Cord Blood Bank Network. The
patient then received a conditioning regimen consisting of fludarabine, intravenous busulfan, and total body irradiation.
Successful engraftment was obtained. The bone marrow examination on day 28 revealed trilineage engraftment, and
chimerism analysis by variable number of tandem repeat polymerase chain reaction confirmed complete donor
chimerism. At that time, conventional cytogenetics of the bone marrow aspirate showed 20 out of 20 metaphases with
the 47, XXY karyotype characteristic of Klinefelter syndrome. Klinefelter syndrome is the most common genetic
cause of human male infertility with a reported prevalence of 0.1–0.2% in the general population. In Japan Cord
Blood Bank Network, there is no informed consent from parents about the possibility that post-unrelated cord blood
transplantation patient evaluation may reveal donor-origin inherited diseases including cytogenetic abnormality.
It is desirable to have opportunities in Japan discussing whether parents will be notified of the possibility that
post-unrelated cord blood transplantation evaluation may reveal donor-derived illness incidentally.
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The use of unrelated cord blood (CB) as a source of
hematopoietic stem cells has been increasing in Japan.
Indeed, more than a thousand unrelated cord blood
transplantations (UCBTs) are performed annually in Japan
(Japanese Cord Blood Bank Network, 2014). One of the
distinct disadvantages of cord blood unit use is the lack of
a significant clinical history from the donor. To compen-
sate for this lack, the Japanese Cord Blood Bank Network
screens the donor’s parents for genetic diseases, screens
placental and maternal blood for infectious diseases, and
performs blood and HLA typing. In addition, the Japanese
Cord Blood Bank Network has a mandatory quarantine
period of 6 months so that units cannot be used until a
minimal amount of adverse medical event data on the
donor can be obtained (Moore et al. 2005).
The informed consent for cord blood donation is ob-
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in any medium, provided the original work is por infant. To confirm engraftment after UCBT and evalu-
ate the status of the primary disease, cytogenetic analysis
of bone marrow is performed routinely. These analyses
identify indirectly the karyotype of donor cells. Here, we
report the case of a UCBT recipient whose post-transplant
karyotype analysis revealed 47, XXY.Case description
A 65-year-old Japanese male was admitted to our hos-
pital for UCBT in 2012.
In 2003, he was diagnosed with follicular lymphoma
stage IVA, and treated with rituximab-containing chemo-
therapy resulting in a first complete remission (CR). His
first relapse occurred in 2004 and treatment consisted
of three courses of rituximab and the CHASE regimen
(Ogura et al. 2003). His second relapse occurred in 2007
and treatment with rituximab, the CHASE regimen, and
then autologous peripheral blood stem cell transplantation
led to a third CR (Kamezaki et al. 2007). His third relapse
occurred in 2009, and was treated with 90yttrium-ibritu-
momab-tiuxetan, obtaining a fourth CR.s is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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cells in the peripheral blood, and bone marrow exam-
ination confirmed the diagnosis of therapy-related
myelodysplastic syndrome RAEB-1 with the abnormal
karyotype of 45, XY, del5q, del7q, del12p, -13. His
International Prognostic Scoring System (IPSS) score
was Int-2 (Greenberg et al. 1997). A cord blood unit
from a male donor was obtained from the Japan Cord
Blood Bank Network, was mismatched at 2 HLA loci,
contained 1.93 × 107/kg of nucleated cells, and contained
0.62 × 105/kg of CD34-positive cells. The patient then
received a conditioning regimen consisting of fludarabine
(30 mg/m2 on days –7 to –2), intravenous busulfan
(3.2 mg/kg on days –6 to –3), and total body irradi-
ation (4 Gy on day –2) (Takagi et al. 2010) as well as
graft-versus-host disease (GVHD) prophylaxis consisting
of intravenous tacrolimus (0.02 mg/kg/day) beginning on
day –1 and short-term methotrexate on days 1, 3, and 6
(5 mg/m2). Engraftment was obtained. A neutrophil count
of > 0.5 × 103/L and a platelet count of > 20 × 103/L were
achieved on days 14 and 42, respectively. He developed
acute GVHD grade II of the gut and was successfully
treated with hydrocortisone. The bone marrow examin-
ation on day 28 revealed trilineage engraftment, and
chimerism analysis by variable number of tandem repeat
using the AmpFLSTR® SGM Plus® PCR Amplification
Kit (Applied Biosystems) confirmed the establishmentFigure 1 The bone marrow examination on day 28 revealed trilineag
marrow aspirate showed 20 out of 20 metaphases with 47, XXY karyoof complete donor chimerism. At that time, conventional
cytogenetics of the bone marrow aspirate showed 20 out
of 20 metaphases with 47, XXY (Figure 1). On day 130,
peripheral blood examination revealed emergence of
blasts, and on day 137, bone marrow examination showed
recurrence of myelodysplastic syndrome. At that time, chi-
merism analysis revealed mixed chimerism of 64.4% donor
origin, and conventional cytogenetics of the bone marrow
aspirate showed 14 out of 16 metaphases with 47, XXY,
and 2 out of 16 metaphases with 45, XY, -3, del5q, add7q,
del12p, -13, + mar. Gradually cytopenia worsened and the
patient was treated conservatively.
Discussion
Klinefelter syndrome was first described in 1942 as an
endocrine disorder characterized by small firm testes,
gynecomastia, hypogonadism, and higher than normal
concentrations of follicle-stimulating hormone (FSH)
(Klinefelter et al. 1942). About 80% of cases are due to
the congenital numerical chromosome aberration 47,
XXY (Lanfranco et al. 2004). Klinefelter syndrome is the
most common genetic cause of human male infertility
with a reported prevalence of 0.1–0.2% in the general
population, but many cases remain undiagnosed because
of substantial variation in clinical presentation and in-
sufficient professional awareness of the syndrome itself.
Abramsky and Chapple calculated that 10% of expectede engraftment and conventional cytogenetics of the bone
type.
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childhood or adult life because of hypogonadism, gyne-
comastia, or infertility, leaving 64% undiagnosed (Abramsky
and Chapple 1997). Indeed, Halaburda et al. reported
diagnosis of Klinefelter syndrome in the donor after
transplantation of allogeneic peripheral blood stem cells
into a 35-year-old recipient with acute myelogenous
leukemia from his 37-year-old HLA-identical brother
(Halaburda et al. 2000). In Japan, more than a thousand
UCBTs have been performed annually, and the prevalence
of Klinefelter syndrome is supposed to be 0.1–0.2%. A
cytogenetic survey conducted in Japan on 14,835 liveborn
infants (7608 males and 7227 females) showed that 93
infants (6.27 per 1000) had a major chromosome abnor-
mality, and of these, seven male (0.92 per 1000 male)
infants had a 47, XXY karyotype. Thus, UCBT from male
donors with Klinefelter syndrome like ours seems to hap-
pen continuously. In the Japanese Cord Blood Network,
mothers must provide informed consent whether or not
they want to know their infectious disease screening
results (Japanese Cord Blood Bank Network, 2014). How-
ever, early in the course of their pregnancies, most mothers
have been checked for infectious diseases as part of a rou-
tine screening program in Japan. Notably, parents whoTable 1 Reported cases of donor-derived chromosomal abnorm
Type of transplantation Donor type Donor age Donor sex Chrom
BMT R 29 M 46, XY
BMT R 28 F 47, XX
BMT R 19 F 45, XX
BMT R NA NA 47, XX
BMT R NA NA 47, XX
BMT R NA NA 45, X/
BMT R NA NA 46, XX
BMT R 13 F Down
BMT R 26 M Down
BMT R 23 F Down
BMT R 17 F Down
BMT R 25 F 47, XX
BMT R 48 F 47, XX
PBSCT R 37 M 47, XX
CBT U 0 F 47, XX
NA R 2.5 F 45, X/
NA R 54 F 45, X/
BMT R 23 M 46, XX
BMT & CBT R 11 month M 47, XX
BMT U 26 M 47, XY
BMT U NA M 45, XY
Abbreviations: BMT: bone marrow transplantation, PBSCT: peripheral blood stem cel
not available, M: male, F: female.provide informed consent are not told about the possibil-
ity that donor-origin inherited diseases including cytogen-
etic abnormalities may develop post-UCBT. The prognosis
of these inherited diseases may range from very mild to
dismal. Among them, Klinefelter syndrome is a disease
that with early recognition and hormonal treatment of
the disorder can be managed, and quality of life can be
substantially improved (Mehta and Paduch 2012). Post-
UCBT, cytogenetic analysis of bone marrow is performed
routinely. These analyses identify indirectly the karyotype
of donor cells. Various types of constitutional abnormal-
ities of karyotype have been reported to be transmitted
after allogeneic hematopoietic stem cell transplantation
as shown in Table 1 (Graze et al. 1977; Becher et al.
1986; Kuffel et al. 1991; Barquinero et al. 1995; Halaburda
et al. 2000; Moore et al. 2005; Manola et al. 2006; Ismail
et al. 2007; Balci et al. 2008; Frey et al. 2008; Consoli et al.
2011). All donors with Down syndrome were identified
before stem cell donations as the manifestations of Down
syndrome were evident. On the contrary, most donors
with numerical abnormalities of sex chromosomes were
diagnosed after transplantation; it means the manifesta-
tions of numerical abnormalities of sex chromosomes
were varying much and post-transplant chromosomalalities in recipients with allogeneic stem cell transplantations
osomal abnormalities Timing of the
diagnosis
References
, t(18q+;22q-) Before transplant Graze et al. 1977
X After transplant Becher et al. 1986
; rob t(14;14) After transplant Becher et al. 1986
Y NA Kuffel et al. 1991
Y NA Kuffel et al. 1991
46, XX NA Kuffel et al. 1991
/47, XX, +mar NA Kuffel et al. 1991
syndrome Before transplant Barquinero et al. 1995
syndrome Before transplant Barquinero et al. 1995
syndrome Before transplant Barquinero et al. 1995
syndrome Before transplant Barquinero et al. 1995
X After transplant Barquinero et al. 1995
X After transplant Barquinero et al. 1995
Y After transplant Halaburda et al. 2000
X After transplant Moore et al. 2005
46, XX After transplant Manola et al. 2006
46, XX After transplant Manola et al. 2006
/46, XX, dic(Y;22)(p11.2;p11.2) After transplant Ismail et al. 2007
Y Before transplant Balci et al. 2008
, +8 After transplant Frey et al. 2008
, der(14;21)(q10;q10) After transplant Consoli et al. 2011
l transplantation, CBT; cord blood transplantation R: related, U: unrelated, NA:
Kawaguchi et al. SpringerPlus 2014, 3:72 Page 4 of 4
http://www.springerplus.com/content/3/1/72analysis of recipients revealed these numerical abnormal-
ities. In the setting of UCBT, as far as we know, only one
case of the donor-derived 47, XXX karyotype has been
reported in the literature (Moore et al. 2005). The Netcord
and Foundation for Accreditation of Cellular Therapy
(NETCORD-FACT) international standards for cord blood
collection, banking, and release for administration recom-
mends in the informed consent section that the cord blood
bank “maintain linkage for the purpose of notifying the
infant donor’s mother or family and/or her physician of
communicable or genetic diseases, whenever possible”
(International Standards for Cord Blood Collection, Bank-
ing, and Release for Administration 2013). On the contrary,
in Japan Cord Blood Banking Network, there is no in-
formed consent from parents about the possibility that
post-UCBT patient evaluation may reveal donor-origin
inherited diseases including cytogenetic abnormality. It
is a matter of great delicacy. Some parents may want to
know their child’s abnormality, and others may not
(Sugarman et al. 2002). It is desirable to have opportun-
ities in Japan discussing whether parents will be notified of
the possibility that post-UCBT evaluation may reveal
donor-derived illness incidentally.
Conclusions
We described donor-derived cytogenetic abnormalities of
47, XXY in the recipient of UCBT. It is desirable to have
opportunities in Japan discussing whether parents will be
notified of the possibility that post-UCBT evaluation may
reveal donor-derived illness incidentally.
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